Sunday, November 8, 2026

One Less Newspaper in Europe

Portuguese business daily Diário Económico ceased print publication on March 18, 2016, after 27 years. Director Gonçalo Faria de Carvalho announced the "suspension of the paper edition" amid severe financial difficulties at parent company Ongoing.

LM Salvado
LM Salvado

March 18, 2016

Portuguese financial daily last printed edition
Portuguese business daily “Diario Economico” has left the newspaper stands. They have ceased printing its newspaper and became a digital-only publication. The paper has long been going through severe financial difficulties. Its director, Gonçalo Faria de Carvalho, announced the "suspension of the paper edition." The last printed edition is hitting the stands on March 18, 2016 with a big "thank you" on the front page. On the back page, an administration note says "The paper edition is now suspended, which we all hope to be temporary." What remains in operation is the online edition and the ETV (Economico TV) cable channel. The newspaper is owned by the Ongoing group who has already recognized the publication is going through a "difficult period." The newspaper was printed for 27 years (since 1989) and employs about 150 people today. The company has had successive negative annual results and owes the tax authorities, social security, and wages to some of its workers.
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com